RxDoctor Payments Data

Jacqueline Gillern

Psychiatric/Mental Health · Waymart, PANPI 1063982759

Payments from drug & device makers

$4,661in general payments, 2019–2025

Across 238 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$700
  • AbbVie$692
  • Otsuka America Pharmaceutical, Inc.$630
  • Johnson & Johnson$501
  • Supernus Pharmaceuticals, Inc.$476
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$439
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$4,661100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,661 in reported general payments places this provider in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,177
Medicare patients
73
Services billed
226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$96,689
VraylarCariprazine Hcl13$18,161
Aripiprazole34$4,667
Chlorpromazine Hcl13$2,508
Venlafaxine Hcl ErVenlafaxine Hcl50$2,134
Duloxetine Hcl19$1,174
Bupropion XlBupropion Hcl29$925
Buspirone Hcl62$820
Hydroxyzine Hcl41$685
Quetiapine Fumarate44$555
Divalproex Sodium ErDivalproex Sodium17$457
Vilazodone Hcl11$427
Prazosin Hcl24$383
Risperidone37$349
Olanzapine26$345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$700$96,68916 claims
AbbVieVraylar$692$18,16113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Waymart

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →